Thymmune Therapeutics
Cambridge
About Thymmune Therapeutics
Thymmune Therapeutics is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $44.0M
- Funding stage: Seed
- Last round: Grant (Sep 2023)
- Website: thymmune.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/thymmune-therapeutics-13869 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.